A peer-reviewed article published in JACC: Advances has demonstrated that a risk prediction algorithm incorporating HeartBeam's credit card-sized ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study, which evaluated 184 patients, found that the algorithm achieved an area under the curve (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms. When a personal, symptom-free baseline ECG was available for comparison, the AUC rose to 92.9%. The results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program.
The study, published in JACC: Advances, highlights the potential of HeartBeam's technology to transform cardiac care. HeartBeam (NASDAQ: BEAT) is a medical technology company focused on providing powerful cardiac insights through portable devices. The company's credit card-sized ECG device is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG. This platform technology is intended for use wherever the patient is, enabling physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to its technology. The results of this study are significant because they demonstrate the potential for the HeartBeam System to be used for heart attack detection, which could have a major impact on patient outcomes. Early and accurate identification of heart attack risk is critical for timely intervention and can reduce mortality and morbidity associated with acute coronary syndromes.
The implications of this research are far-reaching. If the HeartBeam System is approved for heart attack detection, it could enable patients to monitor their cardiac health from home and seek care proactively. This could reduce the burden on emergency departments and healthcare systems, as well as improve access to cardiac care in remote or underserved areas. The ability to compare a current ECG to a personal baseline enhances the accuracy of risk assessment, potentially reducing false alarms and unnecessary hospital visits.
The study's findings are a step forward in the clinical program for the HeartBeam System. The company's broader mission is to redefine the future of cardiac health management by providing actionable heart intelligence. As the technology continues to evolve, it may become an integral part of routine cardiac monitoring, similar to how blood pressure cuffs are used today. For more information about the study and HeartBeam's technology, visit the full press release here.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These include factors beyond management's control, as detailed in the company's filings with the SEC. Undue reliance should not be placed on forward-looking statements, which are based on information available as of the date of this article.
